Dr. Reddy's Laboratories Limited Stock Price Today (NSE: DRREDDY)
Fundamental Score
Dr. Reddy's Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Dr. Reddy's Laboratories Limited share price today is ₹1180.00, down 1.98% on NSE/BSE as of 8 October 2026. Dr. Reddy's Laboratories Limited (DRREDDY) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹98.53K (Cr). The 52-week high for DRREDDY share price is ₹1414.90 and the 52-week low is ₹1101.00. At a P/E ratio of 30.50x, DRREDDY is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 11.75% and a debt-to-equity ratio of 0.17.
Dr. Reddy's Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Dr. Reddy's Laboratories Limited share price chart: -0.67% return over the past month. 52-week high ₹1414.90, 52-week low ₹1101.00.
Dr. Reddy's Laboratories Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1197.30 | ₹1201.20 | ₹1167.20 | ₹1180.00 | 22.79L (Cr) | |
| ₹1208.00 | ₹1222.80 | ₹1192.20 | ₹1203.80 | 17.55L (Cr) | |
| ₹1207.00 | ₹1212.70 | ₹1195.00 | ₹1208.00 | 16.38L (Cr) | |
| ₹1198.00 | ₹1206.60 | ₹1189.00 | ₹1203.00 | 30.76L (Cr) | |
| ₹1233.00 | ₹1233.90 | ₹1194.90 | ₹1206.20 | 26.08L (Cr) | |
| ₹1242.20 | ₹1244.60 | ₹1214.20 | ₹1233.00 | 40.26L (Cr) | |
| ₹1243.20 | ₹1252.80 | ₹1229.00 | ₹1251.90 | 53.47L (Cr) | |
| ₹1211.60 | ₹1229.80 | ₹1204.00 | ₹1221.00 | 34.02L (Cr) | |
| ₹1204.50 | ₹1207.80 | ₹1193.40 | ₹1201.00 | 10.01L (Cr) | |
| ₹1210.90 | ₹1213.90 | ₹1197.00 | ₹1200.40 | 16.68L (Cr) |
Dr. Reddy's Laboratories Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1233.00 | ₹1233.90 | ₹1167.20 | ₹1180.00 | -4.30% | |
| ₹1166.50 | ₹1252.80 | ₹1130.00 | ₹1233.00 | +5.70% | |
| ₹1166.20 | ₹1208.10 | ₹1154.40 | ₹1154.40 | -1.01% | |
| ₹1351.00 | ₹1390.40 | ₹1101.00 | ₹1148.10 | -15.02% | |
| ₹1310.10 | ₹1414.90 | ₹1248.40 | ₹1357.10 | +3.59% | |
| ₹1322.90 | ₹1346.80 | ₹1230.00 | ₹1303.50 | -1.47% | |
| ₹1280.00 | ₹1375.90 | ₹1167.50 | ₹1322.90 | +3.35% | |
| ₹1252.60 | ₹1337.30 | ₹1221.20 | ₹1254.90 | +0.18% | |
| ₹1189.50 | ₹1327.00 | ₹1167.10 | ₹1286.30 | +8.14% | |
| ₹1270.00 | ₹1270.00 | ₹1148.40 | ₹1218.10 | -4.09% | |
| ₹1263.90 | ₹1293.00 | ₹1241.30 | ₹1271.40 | +0.59% | |
| ₹1196.90 | ₹1262.40 | ₹1187.90 | ₹1258.80 | +5.17% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Dr. Reddy's Laboratories Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Dr. Reddy's Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DRREDDY across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Operating Margins (25.66%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (12.09% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (16.54% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (15.39x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.80)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹11252.70 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 51.86%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Profit Decline Concern (-68.67%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-5.51%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-15.59% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Low Promoter Commitment (26.64%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Dr. Reddy's Laboratories Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Dr. Reddy's Laboratories Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab...Selected✓ DRREDDY • 500124 | 41/100 | ₹1180.00₹1180 | ₹98530.00₹98530.00 | 30.50Average 30.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Glenmark Pharmaceuticals LimitedGlenmark Pharma... GLENMARK • 532296 | 70.7/100 | ₹2408.40₹2408 | ₹67965.05₹67965.05 | 37.80Average 37.8 Average | 0.00%Poor 0.00% Poor | 18.58%Good 18.58% Good | 0.00Excellent 0.0 Excellent | 25.68%Excellent 25.68% Excellent | 9.19%Good 9.19% Good | 0.11% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Dr. Reddy's Laboratories Limited PE Ratio History
Historical price-to-earnings ratio for DRREDDY — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹67.78 | ₹1271.40 | 18.8x |
| FY 2024 | ₹66.80 | ₹1388.50 | 20.8x |
| FY 2023 | ₹54.18 | ₹1159.58 | 21.4x |
| FY 2022 | ₹28.34 | ₹847.51 | 29.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Dr. Reddy's Laboratories Limited Dividend History
Annual cash dividends paid by DRREDDY — dividend yield 0.65%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹666.20 Cr |
| FY 2024 | ₹664.80 Cr |
| FY 2023 | ₹497.90 Cr |
| FY 2022 | ₹414.60 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Dr. Reddy's Laboratories Limited Quarterly Performance
Latest quarterly metrics for DRREDDY — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-5.51%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-68.67%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
12.09%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
16.54%
Compounded annual net profit growth over 5 years
Dr. Reddy's Laboratories Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for DRREDDY — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Dr. Reddy's Laboratories Limited Financial Statements
Annual income statement, balance sheet and cash flow for Dr. Reddy's Laboratories Limited (DRREDDY) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Dr. Reddy's Laboratories Limited
About DRREDDY (Dr. Reddy's Laboratories Limited)
Dr. Reddy's Laboratories Ltd is a global pharmaceutical powerhouse, carving its niche in the intricate landscape of healthcare. They are more than just a manufacturer; they are res...earchers, innovators, and dedicated professionals striving to improve access to quality medicines worldwide. The company has a strong international presence, impacting markets across diverse regions with its expansive portfolio. Their commitment extends beyond profit margins, reflecting a genuine dedication to patient well-being and fostering a healthier future through the development, production, and distribution of impactful pharmaceutical solutions. Dr. Reddy's operates through distinct, yet interconnected divisions, each playing a vital role in the company's overall success. One segment focuses on crafting and delivering generic medications, making treatments more affordable and accessible to a wider population. Another concentrates on pharmaceutical services and active pharmaceutical ingredients, supplying the building blocks for other pharmaceutical companies to create their own formulations. This strategic combination of capabilities allows Dr. Reddy's to navigate the pharmaceutical value chain with agility and resilience, maintaining a competitive edge in a rapidly evolving industry. Dr. Reddy's unwavering focus on research and development fuels its ability to address unmet medical needs and stay ahead of the curve. They invest heavily in innovation, constantly seeking new ways to improve existing treatments and discover novel therapies for a range of diseases. This commitment to scientific advancement is deeply ingrained in the company's culture, driving its progress and solidifying its position as a trusted and respected leader in the global pharmaceutical arena. Their efforts ultimately aim to provide better healthcare solutions to those who need them most.
Company Details
Key Leadership
DRREDDY Share Price: Frequently Asked Questions
What is the current share price of Dr. Reddy's Laboratories Limited?
Dr. Reddy's Laboratories Limited (DRREDDY) trades at ₹1180.00 on NSE and BSE. Market cap ₹98.53K (Cr). Educational data only.
What is the P/E ratio of Dr. Reddy's Laboratories Limited?
Dr. Reddy's Laboratories Limited has a P/E of 30.50x vs industry average 34.89x.
What is the Bull Run score for Dr. Reddy's Laboratories Limited?
Dr. Reddy's Laboratories Limited has a Bull Run score of 41/100 based on 25+ financial parameters.
Does Dr. Reddy's Laboratories Limited pay dividends?
Dr. Reddy's Laboratories Limited has a dividend yield of 0.65%. Past dividends don't guarantee future payments.
What is the ROE of Dr. Reddy's Laboratories Limited?
Dr. Reddy's Laboratories Limited has ROE of 11.75%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Dr. Reddy's Laboratories Limited?
Dr. Reddy's Laboratories Limited has debt-to-equity of 0.17.
Is Dr. Reddy's Laboratories Limited a good investment?
Bull Run gives Dr. Reddy's Laboratories Limited a score of 41/100. This is not investment advice — consult a SEBI-registered advisor.